Post-market surveillance has evolved from a largely reactive complaint-tracking function into a proactive, data-driven regulatory obligation. Under EU MDR 2017/745, Article 83 requires manufacturers to plan, establish, document, implement, maintain, and update a PMS system that is an integral part of the quality management system. The FDA similarly expects PMS activities to feed back into design controls, risk management, and corrective action processes. Manufacturers who treat PMS as a compliance checkbox rather than a genuine intelligence system expose themselves to regulatory risk and miss opportunities to improve device performance.
Core Components of a Compliant PMS System
A robust PMS system must address both data collection and data analysis. The following components are expected by both FDA and EU MDR frameworks:
- Complaint handling and MDR/vigilance reporting: Systematic intake, assessment, and reporting of complaints and adverse events, with clear criteria for reportability and defined investigation timelines
- Literature surveillance: Ongoing review of published scientific and clinical literature relevant to the device and comparable devices, with documented search strategies and assessment records
- Real-world performance data: Collection and analysis of registry data, sales returns, service records, and customer feedback beyond formal complaints
- Benchmark data: Analysis of equivalent or similar devices on the market to provide comparative context for the device's safety and performance profile
- Trend analysis: Statistical analysis of complaint and event data to identify emerging signals before they reach reportable thresholds
EU MDR PMS Reporting Outputs
EU MDR requires manufacturers to produce two types of PMS reports, depending on device risk class. Class I manufacturers must prepare a Post-Market Surveillance Report (PMSR), which summarizes PMS data and conclusions at appropriate intervals, typically annually. Class IIa, IIb, and III manufacturers must prepare a Periodic Safety Update Report (PSUR) at defined frequencies - annually for Class III and implantable devices, and every three years for Class IIa devices under the proposed December 2025 amendments (or annually under current rules). The PSUR must include a benefit-risk determination and conclusions about the continued acceptability of identified risks.
FDA Post-Market Surveillance Expectations
The FDA's PMS framework is less prescriptive than EU MDR in terms of specific report formats, but the agency can order a manufacturer to conduct a post-market surveillance study under Section 522 of the FD&C Act for certain Class II and III devices. FDA inspection guidance for the QMSR era emphasizes the expectation that complaint data should demonstrably feed into CAPA processes and design reviews. Investigators will look for evidence that complaint trend analysis is being performed and that the results are reviewed at management review meetings with documented follow-up actions.
Building an Integrated PMS System
The most effective PMS systems are integrated into the QMS rather than operated as a standalone function. This means connecting complaint handling records to the risk management file so that identified hazards from real-world use can be assessed against the risk acceptance criteria established during design. It also means ensuring that literature surveillance findings are reviewed by the clinical evaluation team so that new scientific evidence can be incorporated into the clinical evaluation report (CER) update cycle. Sequence Group can assist manufacturers in designing and implementing PMS systems that meet both FDA and EU MDR requirements within a single, integrated documentation architecture.
Common PMS Deficiencies Found During Inspections and Audits
Based on patterns in FDA 483 observations and notified body audit findings, the most frequent PMS deficiencies include inadequate literature search methodologies that fail to capture relevant clinical evidence, complaint rate trend analysis that is not statistically grounded, PSURs that restate complaint data without drawing regulatory conclusions, and missing linkages between PMS outputs and the device's risk management file. Addressing these deficiencies proactively is far less costly than responding to regulatory action after an audit finding.
Frequently Asked Questions
What is the difference between a PMSR and a PSUR under EU MDR?
Under EU MDR, Class I manufacturers must prepare a Post-Market Surveillance Report (PMSR), which summarizes PMS data and conclusions at appropriate intervals. Class IIa, IIb, and III manufacturers must prepare a Periodic Safety Update Report (PSUR), which includes a benefit-risk determination and conclusions about the continued acceptability of identified risks. The PSUR frequency is annual for Class III and implantable devices and currently annual for Class IIa devices under the rules in force.
What components must a compliant PMS system include?
A robust PMS system must cover complaint handling and MDR/vigilance reporting with defined investigation timelines; ongoing literature surveillance with documented search strategies; collection and analysis of real-world performance data beyond formal complaints; benchmark data comparing the device to equivalent or similar products on the market; and statistical trend analysis to identify emerging signals before they reach reportable thresholds. These components are expected by both FDA and EU MDR frameworks.
What are the most common PMS deficiencies found during inspections and audits?
Frequently cited deficiencies include literature search methodologies that fail to capture relevant clinical evidence, complaint rate trend analysis that is not statistically grounded, PSURs that restate complaint data without drawing regulatory conclusions, and missing linkages between PMS outputs and the device's risk management file. Addressing these proactively is far less costly than responding to regulatory action after an audit finding.